Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer
Study Information
Alliance Study ID: NCCTG-N0436
NCT Study ID (ClinicalTrials.gov): NCT00275041
Disease or Cancer Type: Breast Cancer
Alliance Study Chair: Timothy Hobday, MD
Status: COMPLETED
Study Description
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving irinotecan together with cetuximab may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving irinotecan together with cetuximab works in treating patients with metastatic breast cancer.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information